HRP20170734T1 - Povećana biodostupnost lijeka u terapiji naltreksonom - Google Patents

Povećana biodostupnost lijeka u terapiji naltreksonom Download PDF

Info

Publication number
HRP20170734T1
HRP20170734T1 HRP20170734TT HRP20170734T HRP20170734T1 HR P20170734 T1 HRP20170734 T1 HR P20170734T1 HR P20170734T T HRP20170734T T HR P20170734TT HR P20170734 T HRP20170734 T HR P20170734T HR P20170734 T1 HRP20170734 T1 HR P20170734T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
naltrexone
bupropion
use according
Prior art date
Application number
HRP20170734TT
Other languages
English (en)
Croatian (hr)
Inventor
Shawn Flanagan
Eduardo Dunayevich
Original Assignee
Orexigen Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170734(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics, Inc. filed Critical Orexigen Therapeutics, Inc.
Publication of HRP20170734T1 publication Critical patent/HRP20170734T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
HRP20170734TT 2010-12-03 2011-12-02 Povećana biodostupnost lijeka u terapiji naltreksonom HRP20170734T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41939510P 2010-12-03 2010-12-03
PCT/US2011/063177 WO2012075459A1 (en) 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy
EP11845186.3A EP2646031B9 (en) 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy

Publications (1)

Publication Number Publication Date
HRP20170734T1 true HRP20170734T1 (hr) 2017-08-11

Family

ID=46172304

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20170734TT HRP20170734T1 (hr) 2010-12-03 2011-12-02 Povećana biodostupnost lijeka u terapiji naltreksonom
HRP20240115TT HRP20240115T1 (hr) 2010-12-03 2011-12-02 Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom
HRP20210618TT HRP20210618T1 (hr) 2010-12-03 2021-04-19 Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20240115TT HRP20240115T1 (hr) 2010-12-03 2011-12-02 Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom
HRP20210618TT HRP20210618T1 (hr) 2010-12-03 2021-04-19 Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom

Country Status (27)

Country Link
US (1) US20130245056A1 (OSRAM)
EP (4) EP3222280B1 (OSRAM)
JP (5) JP6008866B2 (OSRAM)
KR (5) KR102391511B1 (OSRAM)
CN (1) CN103313711A (OSRAM)
AR (2) AR093182A1 (OSRAM)
AU (2) AU2011336304B2 (OSRAM)
BR (1) BR112013013390A2 (OSRAM)
CA (2) CA2819262C (OSRAM)
CL (1) CL2013001564A1 (OSRAM)
CY (2) CY1118968T1 (OSRAM)
DK (3) DK3884947T3 (OSRAM)
ES (2) ES2866879T3 (OSRAM)
FI (1) FI3884947T3 (OSRAM)
HR (3) HRP20170734T1 (OSRAM)
HU (3) HUE065852T2 (OSRAM)
IL (3) IL226504B (OSRAM)
LT (3) LT3222280T (OSRAM)
MX (2) MX384662B (OSRAM)
PL (3) PL3884947T3 (OSRAM)
PT (3) PT3222280T (OSRAM)
RS (3) RS56014B1 (OSRAM)
RU (1) RU2640561C2 (OSRAM)
SI (3) SI3222280T1 (OSRAM)
SM (3) SMT202100227T1 (OSRAM)
TW (1) TWI618536B (OSRAM)
WO (1) WO2012075459A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639579T3 (es) 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
KR20120124423A (ko) 2010-01-11 2012-11-13 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
PL3884947T3 (pl) * 2010-12-03 2024-05-06 Nalpropion Pharmaceuticals Llc Wzrost biodostępności leku w terapii naltreksonem
RS67076B1 (sr) 2012-06-06 2025-08-29 Nalpropion Pharmaceuticals Llc Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom
WO2016125109A1 (en) * 2015-02-07 2016-08-11 Intas Pharmaceuticals Ltd. Pharmaceutical composition for the treatment of obesity
CN111050801B (zh) * 2017-03-28 2023-03-28 Ldn制药有限公司 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂
EP3482751A1 (en) 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1772147A2 (en) * 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
ES2639579T3 (es) 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
KR20080042092A (ko) 2005-07-27 2008-05-14 오렉시젠 세러퓨틱스 인크. 체중감량 조성물
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
EP1954316A1 (en) 2005-11-28 2008-08-13 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
ES2636657T3 (es) * 2006-06-19 2017-10-06 Alpharma Pharmaceuticals Llc Composición farmacéutica
KR101264789B1 (ko) * 2006-06-30 2013-05-15 엘지디스플레이 주식회사 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
CA2693992C (en) * 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
CN101573103A (zh) 2006-11-09 2009-11-04 奥雷西根治疗公司 用于施用重量减轻药物的单位剂量包装和方法
AR063959A1 (es) * 2006-11-09 2009-03-04 Orexigen Therapeutics Inc Formulaciones farmaceuticas en capas
DK3461503T3 (da) * 2007-04-11 2022-02-14 Biomarin Pharm Inc Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
WO2009035473A2 (en) * 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
PL3884947T3 (pl) * 2010-12-03 2024-05-06 Nalpropion Pharmaceuticals Llc Wzrost biodostępności leku w terapii naltreksonem

Also Published As

Publication number Publication date
MX356801B (es) 2018-06-13
KR102258043B1 (ko) 2021-05-28
KR102391511B1 (ko) 2022-04-26
JP2024071605A (ja) 2024-05-24
AU2011336304B2 (en) 2017-03-30
RU2017144631A3 (OSRAM) 2021-04-13
CY1124331T1 (el) 2022-07-22
CN103313711A (zh) 2013-09-18
JP2019056004A (ja) 2019-04-11
EP3222280A1 (en) 2017-09-27
ES2866879T3 (es) 2021-10-20
HUE065852T2 (hu) 2024-06-28
AU2011336304A1 (en) 2013-07-11
RU2013127423A (ru) 2015-01-10
DK3884947T3 (da) 2024-01-22
EP2646031B1 (en) 2017-02-22
SMT201700232T1 (it) 2017-07-18
KR102105857B1 (ko) 2020-05-04
LT3222280T (lt) 2021-05-10
SMT202400038T1 (it) 2024-03-13
PT3222280T (pt) 2021-04-22
JP2013544290A (ja) 2013-12-12
SMT202100227T1 (it) 2021-07-12
JP2016210809A (ja) 2016-12-15
IL270841A (en) 2020-01-30
CY1118968T1 (el) 2018-01-10
HUE053831T2 (hu) 2021-07-28
CL2013001564A1 (es) 2014-05-02
BR112013013390A2 (pt) 2016-09-06
CA2819262A1 (en) 2012-06-07
EP2646031A4 (en) 2014-04-23
RS62149B1 (sr) 2021-08-31
JP2022060331A (ja) 2022-04-14
PL2646031T3 (pl) 2017-08-31
RS56014B1 (sr) 2017-09-29
US20130245056A1 (en) 2013-09-19
CA3239386A1 (en) 2012-06-07
HUE034393T2 (en) 2018-02-28
KR101984500B1 (ko) 2019-05-31
EP4349369B1 (en) 2025-09-17
KR20200044158A (ko) 2020-04-28
IL279626A (en) 2021-03-01
EP4349369A2 (en) 2024-04-10
EP3884947B1 (en) 2023-11-15
KR20210063473A (ko) 2021-06-01
PT2646031T (pt) 2017-05-25
KR20190058702A (ko) 2019-05-29
IL226504B (en) 2021-01-31
EP4349369A3 (en) 2024-05-15
KR20180069089A (ko) 2018-06-22
JP7025319B2 (ja) 2022-02-24
CA2819262C (en) 2024-05-28
JP6008866B2 (ja) 2016-10-19
MX2013006071A (es) 2013-10-01
HRP20240115T1 (hr) 2024-06-07
KR20140035320A (ko) 2014-03-21
PL3222280T3 (pl) 2021-11-29
LT2646031T (lt) 2017-06-26
RU2017144631A (ru) 2019-02-18
ES2625527T3 (es) 2017-07-19
MX384662B (es) 2025-03-14
RS65198B1 (sr) 2024-03-29
EP2646031B9 (en) 2018-01-10
AR093182A1 (es) 2015-05-27
HRP20210618T1 (hr) 2021-09-17
DK3222280T3 (da) 2021-04-19
AU2017204309A1 (en) 2017-07-13
EP2646031A1 (en) 2013-10-09
EP3222280B1 (en) 2021-01-20
EP3884947A1 (en) 2021-09-29
PL3884947T3 (pl) 2024-05-06
SI3884947T1 (sl) 2024-06-28
SI2646031T1 (sl) 2017-07-31
WO2012075459A1 (en) 2012-06-07
JP6456890B2 (ja) 2019-01-23
FI3884947T3 (fi) 2024-01-30
AR124500A2 (es) 2023-04-05
SI3222280T1 (sl) 2021-11-30
ES2625527T9 (es) 2018-09-25
RU2640561C2 (ru) 2018-01-09
DK2646031T3 (en) 2017-05-22
TW201304780A (zh) 2013-02-01
PT3884947T (pt) 2024-02-16
TWI618536B (zh) 2018-03-21
LT3884947T (lt) 2024-03-12

Similar Documents

Publication Publication Date Title
HRP20170734T1 (hr) Povećana biodostupnost lijeka u terapiji naltreksonom
JP2013544290A5 (OSRAM)
HRP20210239T1 (hr) Tetrahidrobiopterin za liječenje stanja povezanih s povišenim razinama fenilalanina
AU2023200826B2 (en) Administration of berberine metabolites
MX2015011896A (es) Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia.
HRP20141008T1 (hr) Oblik doziranja koji sadrži dva aktivna farmaceutska sastojka u razliäśitim fizikalnim oblicima
JP2009525343A5 (OSRAM)
JP2010525050A5 (OSRAM)
JP2009525985A5 (OSRAM)
HRP20171743T1 (hr) Sastavi i postupci za savladavanje otpornosti na tramadol
HRP20240121T1 (hr) Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine
JP2010527347A5 (OSRAM)
HRP20250615T1 (hr) Tradipitant za upotrebu u liječenju gastropareze
JP2013516493A5 (OSRAM)
JP2017525771A (ja) 体重と体脂肪減少に用いられる組成物およびその医薬品と使用
JP2011510922A5 (OSRAM)
JP2007238598A5 (OSRAM)
WO2011019735A3 (en) Nutritional supplements
JP2013540133A5 (OSRAM)
CN103491959A (zh) Trmp5抑制剂在不减少食物摄入时支持体重减轻
RU2014146562A (ru) Композиция, содержащая альфа-липоевую кислоту и гонокиол, для лечения нейропатий
KR20190134671A (ko) 체중을 감소시키고 체지방을 감소시키기 위한 조성물 및 그의 제약 생성물 및 적용
WO2011108882A3 (ko) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
EP1949900A3 (en) Controlled release solid formulation for oral administration as single dose sachet and method of preparation thereof
IN2012CH05549A (OSRAM)